Table 1.
Patterns of prescriptions for each SSRI
| SSRI name (ATC Code) | ERP+/TAM+ na, (# of prescriptionsb), [range of # per personc] | ERP−/TAM− [n, (%)] na, (# of prescriptionsb), [range of # per personc] | ||
|---|---|---|---|---|
| cases | control | cases | controls | |
| Zimeldine (N06AB02) | 0 | 0 | 0 | 0 |
| Fluoxetine (N06AB03) | 5 (24) [2–11] | 7 (60) [1–32] | 2 (12) [1–11] | 4 (19) [1–9] |
| Citalopram (N06AB04)† | 33 (400) [1–53] | 33 (163) [1–24] | 12 (119) [1–35] | 14 (120) [1–43] |
| Paroxetine (N06AB05) | 6 (23) [1–13] | 4 (16) [1–11] | 1 (2) [2–2] | 5 (39) [5–14] |
| Sertraline (N06AB06) | 13 (86) [1–24] | 15 (85) [1–18] | 6 (28) [1–11] | 4 (78) [1–48] |
| Alaproclate (N06AB07) | 0 | 0 | 0 | 0 |
| Fluvoxamine (N06AB08) | 0 | 0 | 0 | 0 |
| Etoperidone (N06AB09) | 0 | 0 | 0 | 0 |
| Escitalopram (N06AB10)d | 5 (15) [1–6] | 4 (18) [1–12] | 0 | 0 |
a
Number of cases and controls receiving any prescription for each SSRI
b
Total number of prescriptions for each SSRI
c
Range of number of prescriptions per person within group strata (I) expressing the estrogen receptor and receiving at least one year of tamoxifen therapy (ERP+/TAM+), or (II) not expressing the estrogen receptor, never receiving tamoxifen therapy, and surviving at least one year after diagnosis (ERP−/TAM−)
d
In the analysis, we defined citalopram exposure as any prescription for citalopram (N06AB04) or its s-stereoisomer escitalopram (N06AB10)